STOCK TITAN

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Reneo Pharmaceuticals, Inc. will participate in two upcoming investor conferences: Jefferies London Healthcare Conference from November 14-16 in London, UK, and Piper Sandler & Co. Annual Healthcare Conference from November 28-30 in New York, NY. Links to the presentations and webcast will be available on the company's website.
Positive
  • None.
Negative
  • None.

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences.

Jefferies London Healthcare Conference
Date: Tuesday, November 14 – Thursday, November 16, 2023
Location: The Waldorf Hilton, London, UK

Piper Sandler & Co. Annual Healthcare Conference
Date: Tuesday, November 28 – Thursday, November 30, 2023
Location: The Lotte New York Palace, New York, NY

Links to the presentations and webcast will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.

About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com

Matthew Purcell, Pharm.D.
Media Inquiries
Russo Partners, LLC
matthew.purcell@russopartnersllc.com


Reneo Pharmaceuticals will participate in the Jefferies London Healthcare Conference and Piper Sandler & Co. Annual Healthcare Conference.

The Jefferies London Healthcare Conference will take place from November 14 to November 16.

The Jefferies London Healthcare Conference will be held at The Waldorf Hilton in London, UK.

The Piper Sandler & Co. Annual Healthcare Conference will take place from November 28 to November 30.

The Piper Sandler & Co. Annual Healthcare Conference will be held at The Lotte New York Palace in New York, NY.

The presentations and webcast will be available on the Investors section of the Reneo Pharmaceuticals corporate website.
Reneo Pharmaceuticals Inc

NASDAQ:RPHM

RPHM Rankings

RPHM Latest News

RPHM Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About RPHM

reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. many of these diseases are associated with deficits in cellular metabolism and energy production. our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting. we are currently advancing a novel molecule into several diseases. our experienced team of drug development experts, who have collaborated in many successful programs, are dedicated and passionate about finding effective therapies for these complex rare diseases.